Viral Conjunctivitis - Pipeline Review, H2 2014

Published: Nov, 2014 | Pages: 43 | Publisher: Global Markets Direct
Industry: Healthcare | Report Format: Electronic (PDF)

Viral Conjunctivitis - Pipeline Review, H2 2014

Summary

Global Markets Direct's, 'Viral Conjunctivitis - Pipeline Review, H2 2014', provides an overview of the Viral Conjunctivitis's therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Viral Conjunctivitis, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Viral Conjunctivitis and special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides a snapshot of the global therapeutic landscape of Viral Conjunctivitis
- The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities 
- The report reviews key players involved in the therapeutics development for Viral Conjunctivitis and enlists all their major and minor projects
- The report summarizes all the dormant and discontinued pipeline projects 
- A review of the Viral Conjunctivitis products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- A detailed assessment of monotherapy and combination therapy pipeline projects
- Coverage of the Viral Conjunctivitis pipeline on the basis of target, MoA, route of administration and molecule type
- Latest news and deals relating related to pipeline products

Reasons to buy

- Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Develop strategic initiatives by understanding the focus areas of leading companies
- Identify and understand important and diverse types of therapeutics under development for Viral Conjunctivitis
- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
- Devise corrective measures for pipeline projects by understanding Viral Conjunctivitis pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

 Table of Contents
Table of Contents 2
List of Tables 4
List of Figures 4
Introduction 5
Global Markets Direct Report Coverage 5
Viral Conjunctivitis Overview 6
Therapeutics Development 7
Pipeline Products for Viral Conjunctivitis - Overview 7
Pipeline Products for Viral Conjunctivitis - Comparative Analysis 8
Viral Conjunctivitis - Therapeutics under Development by Companies 9
Viral Conjunctivitis - Pipeline Products Glance 10
Clinical Stage Products 10
Early Stage Products 11
Viral Conjunctivitis - Products under Development by Companies 12
Viral Conjunctivitis - Companies Involved in Therapeutics Development 13
Foresight Biotherapeutics, Inc. 13
NanoViricides, Inc. 14
NovaBay Pharmaceuticals, Inc. 15
Panoptes Pharma Ges.m.b.H. 16
Starpharma Holdings Limited 17
Viral Conjunctivitis - Therapeutics Assessment 18
Assessment by Monotherapy Products 18
Assessment by Target 19
Assessment by Mechanism of Action 21
Assessment by Route of Administration 23
Assessment by Molecule Type 25
Drug Profiles 26
astodrimer - Drug Profile 26
Product Description 26
Mechanism of Action 26
R&D Progress 26
EKCCide-I - Drug Profile 28
Product Description 28
Mechanism of Action 28
R&D Progress 28
FST-100 - Drug Profile 29
Product Description 29
Mechanism of Action 29
R&D Progress 29
NVC-638 - Drug Profile 31
Product Description 31
Mechanism of Action 31
R&D Progress 31
NVC-704 - Drug Profile 32
Product Description 32
Mechanism of Action 32
R&D Progress 32
NVC-727 - Drug Profile 33
Product Description 33
Mechanism of Action 33
R&D Progress 33
PP-001 - Drug Profile 34
Product Description 34
Mechanism of Action 34
R&D Progress 34
Viral Conjunctivitis - Recent Pipeline Updates 35
Viral Conjunctivitis - Dormant Projects 38
Viral Conjunctivitis - Discontinued Products 39
Viral Conjunctivitis - Product Development Milestones 40
Featured News & Press Releases 40
May 13, 2013: Starpharma's Dendrimer SPL7013 Demonstrates Potential As Viral Conjunctivitis Treatment 40
May 05, 2010: Foresight Biotherapeutics, Inc 's Drug FST-100 Reduces Infectious Adenoviral Titers And Improves Clinical Signs in Conjunctivitis Model 40
Appendix 42
Methodology 42
Coverage 42
Secondary Research 42
Primary Research 42
Expert Panel Validation 42
Contact Us 43
Disclaimer 43

List of Tables
Number of Products under Development for Viral Conjunctivitis, H2 2014 7
Number of Products under Development for Viral Conjunctivitis - Comparative Analysis, H2 2014 8
Number of Products under Development by Companies, H2 2014 9
Comparative Analysis by Clinical Stage Development, H2 2014 10
Comparative Analysis by Early Stage Development, H2 2014 11
Products under Development by Companies, H2 2014 12
Viral Conjunctivitis - Pipeline by Foresight Biotherapeutics, Inc., H2 2014 13
Viral Conjunctivitis - Pipeline by NanoViricides, Inc., H2 2014 14
Viral Conjunctivitis - Pipeline by NovaBay Pharmaceuticals, Inc., H2 2014 15
Viral Conjunctivitis - Pipeline by Panoptes Pharma Ges.m.b.H., H2 2014 16
Viral Conjunctivitis - Pipeline by Starpharma Holdings Limited, H2 2014 17
Assessment by Monotherapy Products, H2 2014 18
Number of Products by Stage and Target, H2 2014 20
Number of Products by Stage and Mechanism of Action, H2 2014 22
Number of Products by Stage and Route of Administration, H2 2014 24
Number of Products by Stage and Molecule Type, H2 2014 25
Viral Conjunctivitis Therapeutics - Recent Pipeline Updates, H2 2014 35
Viral Conjunctivitis - Dormant Projects, H2 2014 38
Viral Conjunctivitis - Discontinued Products, H2 2014 39